Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

zoetis belgium sa - lokivetmab - muude nahahaiguste valmististes, ained dermatiit, välja arvatud kortikosteroidid - koerad - atoopilise dermatiidi kliiniliste ilmingute ravi koertel.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

leo pharma a/s - takroliimus - dermatiit, atoopiline - muud dermatoloogilised preparaadid - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. esinevad neli või enam korda aastas), kes on olnud esialgse vastuse maksimaalselt kuue nädala jooksul ravi kaks korda päevas takroliimus salvi (kahjustused eemaldatud, peaaegu kustutatud või kergelt kahjustatud).

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

almirall s.a - dimetüülfumaraat - psoriaas - immunosupressandid - sidumisvastased ravimid on näidustatud mõõduka kuni raskekujulise naastulise psoriaasi ravis täiskasvanutel, kes vajavad süsteemset meditsiinilist ravi.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriaas - immunosupressandid - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoriaas - immunosuppressants, interleukiin inhibiitorid, - ilumetri on näidustatud ravi täiskasvanute mõõduka kuni raske psoriaas, kes kandideerivad süsteemne ravi.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

cycle pharmaceuticals (europe) ltd - nitisinoon - türosineemiad - muud alimentary seedetrakti ja ainevahetust tooted, - ravi täiskasvanud ja pediaatriliste patsientide puhul, kellel on kinnitatud diagnoosi pärilik tyrosinemia tüüp 1 (ht-1) koos toidu piiramine türosiini ja fenüülalaniini.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

teva gmbh - fremanezumab - migreenihäired - calcitonin gene-related peptide (cgrp) antagonists - ajovy on näidustatud migreeni profülaktika täiskasvanutel, kellel on vähemalt 4 migreen päeva kuus.

Kesatuan Eropah - Estonia - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosupressandid - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Estonia - Estonia - Ravimiamet

viatris healthcare limited - pimekroliimus - kreem - 10mg 1g 60g 1tk; 10mg 1g 100g 1tk; 10mg 1g 15g 1tk; 10mg 1g 5g 1tk; 10mg 1g 30g 1tk

Estonia - Estonia - Ravimiamet

leo pharma a/s - kaltsipotriool+beetametasoon - geel - 50mcg+0,5mg 1g 15g 1tk; 50mcg+0,5mg 1g 30g 1tk; 50mcg+0,5mg 1g 60g 2tk; 50mcg+0,5mg 1g 60g 1tk